Regeneron Strikes A CHORD With Deafness Gene Therapy

A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.  

Ear of child
• Source: Shutterstock

There are no approved pharmacological therapies for congenital hearing loss and this situation is unlikely to change any time soon. Still, a glimmer of hope has been provided with signs of hearing improvement in a single patient with profound genetic deafness after treatment with Regeneron Pharmaceuticals, Inc.’s gene therapy, DB-OTO.

More from Gene Therapies

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By 

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’

 

The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

 

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Amgen’s Research VP On Goldilocks Viscosity, AI’s Hinge Moment

 
• By 

Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma

More from Advanced Therapies

How Miltenyi Hopes To Help Shape India’s CGT Landscape

 

Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.

Amgen’s Research VP On Goldilocks Viscosity, AI’s Hinge Moment

 
• By 

Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma

Sarepta Shares Plummet On News Of Elevidys Patient Death

 
• By 

The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.